Indeed, miR-16 has a significant additive effect in inhibiting NF-κB activity in MM cells when combined with bortezomib or BAY11-7082 and sensitizes MM-PCs and resident MΦ of the BM-ME to bortezomib treatment. The gene discussed is NFKB1; the disease is Miyoshi myopathy.